Keil Fee, Stahn Simon, Bohmann Ferdinand O, Samp Patrick, Mann Leonhard, Bersch Lukas, Pfeilschifter Waltraud, Bode Felix, Psychogios Marios-Nikos, Schaefer Jan-Hendrik, Grefkes Christian, Hattingen Elke, Berkefeld Joachim, Arendt Christophe T
Institute of Neuroradiology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
Department of Radiology, Hospital Nordwest, Frankfurt am Main, Germany.
Front Neurol. 2025 Apr 2;16:1554691. doi: 10.3389/fneur.2025.1554691. eCollection 2025.
Antithrombotic therapy of acute stroke patients with tandem lesions and emergent carotid artery stenting (CAS) is still a matter of controversial debates. The lack of evidence from dedicated studies favors a variety of clinical practices. The aim of this study was to use German Stroke Registry (GSR) data of selected high-volume centers to analyze the spectrum of antithrombotic regimens and their influence on complication rates and clinical outcome.
We analyzed the GSR-subgroup of patients with tandem lesions treated with a combination of thrombectomy and carotid artery stenting between 2015 and 2020 in experienced stroke centers which included all consecutive cases, and which were willing to share clinical records in addition to registry data. Statistical analyses of kind and onset of CAS-specific antiplatelet therapy (APT) were used to determine the influence of dual APT (DAPT) on clinical outcome and stent-related complications.
In total, 223 patients with tandem lesions treated by stenting and thrombectomy were included. In the periinterventional phase 68 patients (30.5%) had an aggressive DAPT with double antiplatelets (DAPT; 23.7%) given via gastral tube or with GPIIb-IIIa inhibitors intravenously as bridging (13.9%). In the post-interventional phase, the rate of DAPT increased from 38.6% on day one to 65% from day two. Already on day one, the effect of DAPT on the rate of good clinical outcome mRS (modified Rankin Scale) 0-2 at 90 days ( = 86/223; 38.5%) was significant ( < 0.007), and compared with other APT regimens early continuous DAPT from the first postinterventional day increased the odds up to 79.4% ( = 27/34). DAPT during hospitalization showed no increased risk of symptomatic hemorrhage, while post-hospital use reduced stent occlusion ( = 0.016).
Only a minority of the examined GSR patients with tandem lesions had an effective APT during the periinterventional phase up to day 1. Early postinterventional DAPT significantly increased the rate of good clinical outcome and reduced the rate of occlusive stent thrombosis without increasing risks of symptomatic hemorrhage. The apparent lack of standards and moderate rates of good clinical outcomes shows room for improvement and the necessity of further studies.
急性卒中合并串联病变患者的抗栓治疗及急诊颈动脉支架置入术(CAS)仍是备受争议的话题。缺乏专门研究的证据支持多种临床实践。本研究旨在利用德国卒中登记处(GSR)选定的高容量中心的数据,分析抗栓方案的范围及其对并发症发生率和临床结局的影响。
我们分析了2015年至2020年在经验丰富的卒中中心接受取栓术和颈动脉支架置入术联合治疗的串联病变患者的GSR亚组,这些中心纳入了所有连续病例,并且除登记数据外还愿意分享临床记录。对CAS特异性抗血小板治疗(APT)的类型和开始时间进行统计分析,以确定双重APT(DAPT)对临床结局和支架相关并发症的影响。
总共纳入了223例接受支架置入术和取栓术治疗的串联病变患者。在围手术期,68例患者(30.5%)接受了积极的DAPT,其中23.7%通过胃管给予双联抗血小板药物(DAPT),13.9%静脉给予糖蛋白IIb/IIIa抑制剂作为桥接治疗。在介入治疗后阶段,DAPT的比例从第一天的38.6%增加到第二天的65%。在第一天,DAPT对90天时改良Rankin量表(mRS)评分为0 - 2的良好临床结局发生率(= 86/223;38.5%)的影响就很显著(< 0.007),与其他APT方案相比,从介入治疗后第一天开始早期持续DAPT使几率增加高达79.4%(= 27/34)。住院期间的DAPT未显示有症状性出血风险增加,而出院后使用则降低了支架闭塞率(= 0.016)。
在本研究的GSR串联病变患者中,只有少数患者在围手术期直至第1天接受了有效的APT。介入治疗后早期DAPT显著提高了良好临床结局的发生率,降低了闭塞性支架血栓形成的发生率,且未增加有症状性出血的风险。明显缺乏标准以及良好临床结局的适度发生率表明仍有改进空间且有必要进一步研究。